Healthcare | November 18, 2022
Zydus Lifesciences gets exclusive marketing rights for CanAssist Breast
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
MonoFerric, iron isomaltoside 1000 solution for injection/infusion, is a rapid, single dose IV iron developed to reduce the number of infusions
The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
The company has reported total income of Rs. 4138.6 crores during the period ended June 30, 2022.
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
The addition of Sitaglyn and Siglyn to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes
Lacosamide Injection is used to treat partial-onset seizures.
Subscribe To Our Newsletter & Stay Updated
